福瑞股份(300049) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 330,402,239.26, representing a 2.35% increase compared to CNY 322,803,586.32 in the same period last year[5] - Net profit attributable to shareholders decreased by 32.97% to CNY 28,636,734.93 from CNY 42,719,144.08 year-on-year[5] - The company's basic earnings per share decreased by 33.81% to CNY 0.1075 from CNY 0.1624 in the same period last year[5] - The net profit attributable to shareholders was 28.64 million yuan, a decrease of 32.97% year-on-year[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 29.71 million yuan, down 28.05% year-on-year[16] - The decline in net profit was primarily due to increased sales and management expenses aimed at business expansion, resulting in a loss of 1.32 million euros[16] - Net profit for the current period was ¥41,677,439.79, a decrease of 36.38% from ¥65,397,275.18 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 95.74% to CNY 75,323,658.57 compared to CNY 38,481,610.14 in the previous year[5] - The company's cash and cash equivalents increased to ¥596,318,257.83 from ¥566,827,033.12, representing a growth of 5.06%[18] - Cash and cash equivalents at the end of the period increased to CNY 589,243,816.76, compared to CNY 492,907,321.64 at the end of the previous period[26] - The company reported a net cash outflow from investing activities of CNY 41,412,686.89, an improvement from a net outflow of CNY 58,538,490.39 in the previous period[25] - The company generated CNY 366,220,788.19 in cash from sales of goods and services, an increase of 16.6% from CNY 313,974,545.72 in the previous period[24] Investment and Shareholder Information - The company reported a significant increase in investment cash inflows, which rose by 2503.08% to CNY 322,600,000.00 from CNY 12,393,000.00 in the previous year[8] - The company experienced a 237.43% increase in investment income to CNY 942,338.67, attributed to reduced losses from joint ventures and increased financial returns[8] - The number of ordinary shareholders at the end of the reporting period was 21,271[10] - The largest shareholder, Wang Guanyi, holds 11.28% of the shares, totaling 30,054,138 shares[10] - The company has a total of 9,041,120 unrestricted shares held by New Yu Fuchuang Investment Co., Ltd., representing 1.94% of total shares[11] - The top ten shareholders include China Construction Bank with 3,730,895 shares, accounting for 1.40% of total shares[11] - The total number of shares held by the top ten unrestricted shareholders amounts to 43,000,000 shares[11] Expenses and Liabilities - Financial expenses increased by 202.29% to CNY 5,650,844.87 due to higher foreign exchange losses compared to the previous year[8] - Total operating costs increased to ¥266,500,420.63, up from ¥234,675,665.98, reflecting a rise of 13.54%[21] - Total liabilities decreased to ¥892,559,069.90 from ¥930,985,871.23, a reduction of 4.11%[19] - Research and development expenses were ¥22,178,538.10, down from ¥25,436,128.10, a decrease of 12.87%[21] Strategic Management and Other Income - The company's strategic management in medical services led to improved performance in drug sales and managed medical services[16] - The company recognized stock incentive expenses of 7.22 million yuan, contributing to the overall decline in net profit[16] - The exchange loss due to the depreciation of the US dollar against the euro amounted to 8.57 million yuan[16] - Excluding stock incentive expenses and exchange losses, the net profit attributable to shareholders was 43.35 million yuan, reflecting a year-on-year growth of 1.47%[16] - Other comprehensive income attributable to the parent company was CNY -2,225,366.47, improving from CNY -25,028,921.07 in the previous period[22]